

## Erratum to: Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy

Kazuhiko Masuda<sup>1</sup> · Atsushi Ono<sup>1,2,3,4</sup> · Hiroshi Aikata<sup>1,2</sup> · Tomokazu Kawaoka<sup>1,2</sup> · C. Nelson Hayes<sup>1,2,3</sup> · Yuji Teraoka<sup>1,2</sup> · Kana Daijo<sup>1,2</sup> · Yuki Nakamura-Inagaki<sup>1,2</sup> · Kei Morio<sup>1,2</sup> · Hatsue Fujino<sup>1,2</sup> · Hiromi Kan<sup>1,2</sup> · Takuro Uchida<sup>1,2</sup> · Keiichi Masaki<sup>1,2</sup> · Tomoki Kobayashi<sup>1,2</sup> · Takashi Nakahara<sup>1,2</sup> · Grace Naswa Makokha<sup>1,2</sup> · Yizhou Zhang<sup>1,2</sup> · Yuko Nagaoki<sup>1,2</sup> · Daiki Miki<sup>2,3</sup> · Masataka Tsuge<sup>1,2</sup> · Akira Hiramatsu<sup>1,2</sup> · Michio Imamura<sup>1,2</sup> · Hiromi Abe-Chayama<sup>1,2,3</sup> · Yoshiiku Kawakami<sup>1,2</sup> · Hidenori Ochi<sup>1,2,3</sup> · Kazuaki Chayama<sup>1,2,3</sup>

Published online: 29 May 2017

© Japanese Society of Gastroenterology 2017

### Erratum to: J Gastroenterol DOI 10.1007/s00535-017-1348-8

The errors in the publication of the original article have been updated and the details are given below for your reading:

An article note “Kazuhiko Masuda and Atsushi Ono are the co-first authors” should be included.

The second sentence in the subheading “Results” under the “Abstract” section should read as “High HMGB1 at 4 weeks ( $P = 0.025$ ), vascular invasion to the hepatic vein (Vv) ( $P = 0.009$ ), mRECIST

---

Kazuhiko Masuda and Atsushi Ono are the co-first authors.

---

The online version of the original article can be found under doi:10.1007/s00535-017-1348-8.

---

✉ Kazuhiko Masuda  
masu6743@hiroshima-u.ac.jp

✉ Atsushi Ono  
atsushi-o@hiroshima-u.ac.jp

Hiroshi Aikata  
aikata@hiroshima-u.ac.jp

Tomokazu Kawaoka  
kawaokatomo@hiroshima-u.ac.jp

C. Nelson Hayes  
nelsonhayes@hiroshima-u.ac.jp

Yuji Teraoka  
teraoka22@hiroshima-u.ac.jp

Kana Daijo  
kanakana624@hiroshima-u.ac.jp

Yuki Nakamura-Inagaki  
ynakamur@hiroshima-u.ac.jp

Kei Morio  
kmorio@hiroshima-u.ac.jp

Hatsue Fujino  
fujino920@hiroshima-u.ac.jp

Hiromi Kan  
hiromikan@hiroshima-u.ac.jp

Takuro Uchida  
d136452@hiroshima-u.ac.jp

Keiichi Masaki  
masakik8097@hiroshima-u.ac.jp

Tomoki Kobayashi  
tomoki@hiroshima-u.ac.jp

Takashi Nakahara  
nakahara@hiroshima-u.ac.jp

Grace Naswa Makokha  
gnaswa@hiroshima-u.ac.jp

( $P < 0.0001$ ) and Child–Pugh B ( $P = 0.004$ ) were identified as independent predictors of poor overall survival in HAIC treatment.”

The original article was corrected.

---

Yizhou Zhang  
zhangyizhou10@yahoo.co

Yuko Nagaoki  
nagaoki@hiroshima-u.ac.jp

Daiki Miki  
daikimiki@hiroshima-u.ac.jp

Masataka Tsuge  
tsuge@hiroshima-u.ac.jp

Akira Hiramatsu  
akirah@hiroshima-u.ac.jp

Michio Imamura  
mimamura@hiroshima-u.ac.jp

Hiromi Abe-Chayama  
habe@hiroshima-u.ac.jp

Yoshiiku Kawakami  
kamy4419@hiroshima-u.ac.jp

Hidenori Ochi  
hochi@hiroshima-u.ac.jp

Kazuaki Chayama  
chayama@hiroshima-u.ac.jp

<sup>1</sup> Department of Gastroenterology and Metabolism, Applied Life Science, Institute of Biomedical and Health Science, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan

<sup>2</sup> Liver Research Project Center, Hiroshima University, Hiroshima, Japan

<sup>3</sup> Laboratory for Digestive Diseases, Center for Genomic Medicine, The Institute of Physical and Chemical Research (RIKEN), Hiroshima, Japan

<sup>4</sup> Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, 1470 Madison Ave, Box 1123, New York, NY 10029, USA